Wesley L. McKeithan

TL;DR: In this article, the authors used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), generated from 11 healthy individuals and 2 patients receiving cancer treatment, to screen U.S. Food and Drug Administration-approved TKIs for cardiotoxicities by measuring alterations in Cardiomyocyte viability, contractility, electrophysiology, calcium handling, and signaling.

TL;DR: The maturation media designed to provide oxidative substrates adapted to the metabolic needs of human iPSC (hiPSC)-CMs should increase the fidelity of hiPSC-CMs as disease models.

TL;DR: This protocol describes the differentiation of hiPSCs into cardiomyocytes and subsequent cytotoxicity and contractility assays needed to calculate the ‘cardiac safety index’, which models the likelihood that a drug is cardiotoxic.

TL;DR: iPSC-CMs carrying MYBPC3 PTC mutations displayed aberrant calcium signaling and molecular dysregulations in the absence of significant haploinsufficiency of MYB PC3 protein, providing the first evidence of the direct connection between the chronically activated nonsense-mediated decay pathway and HCM disease development.

TL;DR: In the presence of extracellular binding elements (binders), the inert green fluorescent protein (GFP) can form a detectable concentration gradient by diffusion in the developing fly wing (see the Perspective by Barkai and Shilo).